Loading
Life sciences · Journal article
BMC Pulmonary Medicine · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Durvalumab is the standard consolidation therapy after definitive chemoradiotherapy (dCRT) for unresectable stage III non–small-cell lung cancer (NSCLC), whereas sugemalimab has also been increasingly adopted in clinical practice. However, direct comparative evidence between these two programmed death-ligand 1 (PD-L1) inhibitors remains lacking. This study compared the effectiveness and safety of durvalumab and sugemalimab as consolidation therapy after dCRT in a real-world cohort. We retrospectively analyzed 116 patients with unresectable stage III NSCLC who received durvalumab ( n = 62) or sugemalimab ( n = 54) after definitive CRT at a single institution. The primary endpoint was overall survival (OS); secondary endpoints included real-world progression-free survival (rwPFS), treatment duration, and safety. Stabilized inverse probability of treatment weighting (IPTW) was used to balance baseline characteristics. At a median follow-up of 27.1 months, 63 rwPFS events and 35 deaths occurred. After IPTW adjustment, no statistically significant differences were observed in OS (HR, 0.69; 95% CI, 0.30–1.61; P = 0.392) or rwPFS (HR, 1.12; 95% CI, 0.67–1.88; P = 0.654). Immunotherapy type was not an independent prognostic factor. Median treatment duration was 12.0 months with durvalumab and 21.6 months with sugemalimab. Any-grade pneumonitis occurred in 51.6% and 38.9%, respectively ( P = 0.170), and grade ≥ 3 pneumonitis was uncommon (1.6% vs. 1.9%). No treatment-related deaths occurred. In this IPTW-adjusted real-world study, no statistically significant differences in survival outcomes were observed between durvalumab and sugemalimab; both had acceptable safety profiles after dCRT for unresectable stage III NSCLC. Not applicable.